Novo Nordisk A/S Sponsored ADR (NVO)
Novo Nordisk: NVO Stock To $100?
Novo Nordisk's (NYSE: NVO) Wegovy pill introduction in the U.S. may serve as the turning point that transforms a beleaguered GLP‑1 leader into a viable 2x story moving forward, provided it effectively leverages this first‑mover oral advantage into sustainable volume, pricing authority, and pipeline reliability against Eli Lilly. The stock has increased by approximately 17% in the last month, yet it still remains significantly below its 52‑week peak near 94, suggesting potential for a significant rerating if multiple growth drivers are activated simultaneously.
Will NVO's Wegovy Pill Approval for Obesity be a Game Changer in 2026?
Novo Nordisk's FDA-approved Wegovy pill marks the first oral GLP-1 weight loss therapy, aiming to revive momentum and reshape competition in 2026.
Novo Nordisk's Wegovy Pill Now Broadly Available Across U.S.
Novo Nordisk's Wegovy weight-loss pill is now broadly available across the U.S., two weeks after it received U.S. regulatory approval, the Danish drugmaker said.
UK's pharma regulator could issue a decision for Novo's Wegovy pill by year-end
Britain's medicines regulator said on Monday it was reviewing Novo Nordisk's application for an oral 25 milligram version of its weight-loss drug Wegovy and anticipated making a decision before the end of the year.
Why Novo Nordisk (NVO) Outpaced the Stock Market Today
Novo Nordisk (NVO) reached $52.39 at the closing of the latest trading day, reflecting a +2.97% change compared to its last close.
Spotlight on Health ETFs as NVO & LLY Cut Obesity Drug Price in China
Novo Nordisk cuts Wegovy prices in China, which may shift investor focus toward diversified healthcare ETFs.
FDA Approves Novo Nordisk's Wegovy Pill: A Game Changer for 2026
After a year that has been anything but smooth sailing, pharmaceutical giant Novo Nordisk A/S NYSE: NVO is closing out 2025 on a positive note. Shares received a significant 7% boost on Dec. 23.
Novo Nordisk's 'long game' on weight loss drugs sparks hope in science, but the Street is impatient
Novo Nordisk has had a difficult year as investors questioned the company's ability to translate its strides in pioneering GLP-1 drugs to financial gains. Scientists, however, say that Novo's medicine still has potential.
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Novo cuts Wegovy prices in some Chinese provinces, local media reports
Danish drugmaker Novo Nordisk has nearly halved prices of its obesity drug Wegovy in some Chinese provinces, local media Yicai reported on Monday.
Novo Nordisk: Oral Weight-Loss To The Rescue
Novo Nordisk secured FDA approval for the first oral GLP-1 weight-loss drug, Wegovy, positioning it as a sector game changer. NVO's oral Wegovy pill demonstrated superior weight-loss efficacy versus Eli Lilly's orforglipron, with 16.6% mean loss and 34.4% of patients exceeding 20% weight loss. The stock trades at just 15x EPS, near multi-year lows, despite a massive market opportunity projected to quintuple by 2035.
3 Drug Stocks to Buy at a Discount
Eli Lilly is currently leading the market for GLP-1 drugs, taking the pole position from Novo Nordisk. Novo Nordisk just got approval for a GLP-1 pill, which could again upend the dynamics for weight loss drugs.
